These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Challenges with benchmarking of MDMA-assisted psychotherapy. Halvorsen JØ; Naudet F; Cristea IA Nat Med; 2021 Oct; 27(10):1689-1690. PubMed ID: 34635857 [No Abstract] [Full Text] [Related]
5. Is there a case for MDMA-assisted psychotherapy in the UK? Sessa B J Psychopharmacol; 2007 Mar; 21(2):220-4. PubMed ID: 17329304 [TBL] [Abstract][Full Text] [Related]
6. Toward Risk-Benefit Assessments in Psychedelic- and MDMA-Assisted Therapies. Bradberry MM; Gukasyan N; Raison CL JAMA Psychiatry; 2022 Jun; 79(6):525-527. PubMed ID: 35476015 [No Abstract] [Full Text] [Related]
7. [From Adam to ecstacy; legal use of MDMA in the 1970s and 1980s]. Blok G Tijdschr Psychiatr; 2020; 62(8):702-706. PubMed ID: 32816299 [TBL] [Abstract][Full Text] [Related]
8. Compassionate use of psychedelics. Greif A; Šurkala M Med Health Care Philos; 2020 Sep; 23(3):485-496. PubMed ID: 32468195 [TBL] [Abstract][Full Text] [Related]
9. Why MDMA therapy for alcohol use disorder? And why now? Sessa B Neuropharmacology; 2018 Nov; 142():83-88. PubMed ID: 29126911 [TBL] [Abstract][Full Text] [Related]
10. Ethnoracial health disparities and the ethnopsychopharmacology of psychedelic-assisted psychotherapies. Fogg C; Michaels TI; de la Salle S; Jahn ZW; Williams MT Exp Clin Psychopharmacol; 2021 Oct; 29(5):539-554. PubMed ID: 34096755 [TBL] [Abstract][Full Text] [Related]
11. Can MDMA play a role in the treatment of substance abuse? Jerome L; Schuster S; Yazar-Klosinski BB Curr Drug Abuse Rev; 2013 Mar; 6(1):54-62. PubMed ID: 23627786 [TBL] [Abstract][Full Text] [Related]
12. The potential use of N-methyl-3,4-methylenedioxyamphetamine (MDMA) assisted psychotherapy in the treatment of eating disorders comorbid with PTSD. Brewerton TD; Lafrance A; Mithoefer MC Med Hypotheses; 2021 Jan; 146():110367. PubMed ID: 33203569 [TBL] [Abstract][Full Text] [Related]
13. Progress and promise for the MDMA drug development program. Feduccia AA; Holland J; Mithoefer MC Psychopharmacology (Berl); 2018 Feb; 235(2):561-571. PubMed ID: 29152674 [TBL] [Abstract][Full Text] [Related]
14. Premise, promise and challenges of MDMA assisted therapy for PTSD. Madero S; Alvarez OD Eur Neuropsychopharmacol; 2023 May; 70():19-20. PubMed ID: 36806884 [No Abstract] [Full Text] [Related]
15. Can drugs be used to enhance the psychotherapeutic process? Grinspoon L; Bakalar JB Am J Psychother; 1986 Jul; 40(3):393-404. PubMed ID: 2876654 [TBL] [Abstract][Full Text] [Related]
16. Psychedelic drugs-a new era in psychiatry? . Nutt D Dialogues Clin Neurosci; 2019; 21(2):139-147. PubMed ID: 31636488 [TBL] [Abstract][Full Text] [Related]
17. Therapeutic effect of increased openness: Investigating mechanism of action in MDMA-assisted psychotherapy. Wagner MT; Mithoefer MC; Mithoefer AT; MacAulay RK; Jerome L; Yazar-Klosinski B; Doblin R J Psychopharmacol; 2017 Aug; 31(8):967-974. PubMed ID: 28635375 [TBL] [Abstract][Full Text] [Related]
18. MDMA-assisted psychotherapy for posttraumatic stress disorder: A promising novel approach to treatment. Vermetten E; Yehuda R Neuropsychopharmacology; 2020 Jan; 45(1):231-232. PubMed ID: 31455855 [No Abstract] [Full Text] [Related]
19. The potential dangers of using MDMA for psychotherapy. Parrott AC J Psychoactive Drugs; 2014; 46(1):37-43. PubMed ID: 24830184 [TBL] [Abstract][Full Text] [Related]
20. Perceived Benefits of MDMA-Assisted Psychotherapy beyond Symptom Reduction: Qualitative Follow-Up Study of a Clinical Trial for Individuals with Treatment-Resistant PTSD. Barone W; Beck J; Mitsunaga-Whitten M; Perl P J Psychoactive Drugs; 2019; 51(2):199-208. PubMed ID: 30849288 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]